Venetoclax, a selective Bcl-2 inhibitor, effectively counteracts this by downregulating gemcitabine-induced Bcl-2 overexpression, thereby promoting apoptosis and significantly increasing the sensitivity of pancreatic cancer cells to gemcitabine [53]. Here, BCL2 is linked to pancreatic neoplasm.